Nanobiotix

Nanobiotix Interest Coverage

Interest Coverage Ratio of Nanobiotix (NBTX) as of Oct 24, 2026.

Interest Coverage

-

Last updated:

Interest Coverage Ratio of Nanobiotix is 2026 - . Interest Coverage Ratio of Nanobiotix was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanobiotix Stock analysis

What does Nanobiotix do? Nanobiotix, based in Paris, France, is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and unmet medical needs. Its lead product, NBTXR3, uses hafnium oxide nanoparticles to treat various cancers, including sarcoma and lung cancer. The company has a partnership with Lian Oncology for development and commercialization in Asia. Listed on the stock market in December 2020, Nanobiotix employs 97 people. Nanobiotix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanobiotix stock

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Nanobiotix since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Nanobiotix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Nanobiotix

All Key Metrics — Nanobiotix